|
US20080254027A1
(en)
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
WO2008121160A2
(en)
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
|
MX2011000970A
(es)
|
2008-08-29 |
2011-03-15 |
Symphogen As |
Anticuerpos anti-cd5.
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
EP3556858A3
(en)
|
2014-04-09 |
2020-01-22 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
EP3280803B1
(en)
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
AU2017388753A1
(en)
|
2016-12-30 |
2019-07-11 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
SG11201907870VA
(en)
|
2017-02-28 |
2019-09-27 |
Vor Biopharma Inc |
Compositions and methods for inhibition of lineage specific proteins
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
JP2020525537A
(ja)
*
|
2017-06-12 |
2020-08-27 |
エモリー ユニバーシティー |
Ｔ細胞抗原標的キメラ抗原受容体（ｃａｒ）、及び細胞療法での使用
|
|
US11718659B2
(en)
|
2017-08-28 |
2023-08-08 |
The Trustees Of Columbia University In The City Of New York |
CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents
|
|
CN111918877A
(zh)
|
2018-03-14 |
2020-11-10 |
美国卫生和人力服务部 |
抗cd33嵌合抗原受体及其用途
|
|
SG11202011383VA
(en)
*
|
2018-05-31 |
2020-12-30 |
Univ Washington |
Chimeric antigen receptor t cells (car-t) for the treatment of cancer
|
|
CN112823011A
(zh)
*
|
2018-07-09 |
2021-05-18 |
加利福尼亚大学董事会 |
基于t细胞的免疫疗法的基因靶标
|
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
|
US20220133790A1
(en)
*
|
2019-01-16 |
2022-05-05 |
Beam Therapeutics Inc. |
Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
|
|
EP4034138A4
(en)
*
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|